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• Growing number of potential peptide and 
protein drugs valuable in treatment of 
various diseases
• Freeze drying is often employed in 
formulation of protein pharmaceuticals
Challenges in formulation of 
protein pharmaceuticals
• Careful selection of containers (glass and plastic 
surfaces adsorb proteins and peptides)
• Careful selection of excipients
 High risk of aggregation (can be prevented 
using various substances)
 Potential loss of activity
• Need of sterility for parenterals
• Stability and shelf-life
Experience
• Formulation of freeze-dried, conjugated 
mAb kit, ready-to-label with radioisotopes 
(Lu-177)
Isolation of  
rituximab from
Mabthera ®
Conjugation 
and 
purification 
Freeze-drying Radiolabeling
Freeze-drying
1 • Freezing
2 • Primary drying
3 • Secondary drying
http://www.zlpharmapkg.com/pharmaceutical-vials/34516554.html
Freeze-drying
Baolin, L. & Xinli, Z. (2015). Cryopreservation and Freeze-Drying Protocols, Third Edition. Freeze-Drying of Proteins, 23, 459-476.
• Many tests are required for different types 
of assessment of protein formulations
identity, purity, potency and stability of 
formulation 
Proteins can be assayed both in vitro and 
in vivo ...
Thermal analysis
• Differential scanning calorimetry (DSC) 
transitions of confirmation as a function of 
temperature
• Very helpful in designing a suitable freeze-
drying cycle, 
- designing the step of freezing
- effect of added excipients
• The apex of the endothermic peak is the 
transition temperature between native and 
partially unfolded conformations.

Other techniques in design of
freeze-drying process
• Visual inspection / particle size / light 
obscuration 
• Moisture content
UV/VIS spectroscopy
• Protein aggregates scatter UV light and absorbance 
increases – can be used to monitor protein aggregation.
• UV/VIS A280nm/A410nm
VIS spectroscopy
Determination of the concentration of total protein
BRADFORD ASSAY :  
• Binding of protein molecules to Coomassie blue dye 
under acidic conditions results in a color change from 
brown to blue with absorption maximum change from 
465nm to 595nm
BIURET PROTEIN TEST : 
• Under alkaline conditions, substances containing two or 
more peptide bonds form a purple complex with copper 
salts, measurable at 520-570 nm 
FTIR, Raman spectroscopy 
• Methods of choice in assesment of changes that 
happen during freeze-drying
• Vibrational spectra can be used to estimate the 
secondary structure of proteins by inspection of the 
frequencies at which the amide bonds absorb 
infrared radiation 
• Evaluation of the conformation changes, protein–
protein interactions, protein aggregation 
The obtained spectra can 
be compared to aqueous 
reference spectrum, thus 
examining the degree of 
retention of native 
secondary structure
kDa
Electrophoresis
• SDS-PAGE is frequently used in protein analysis, 
especially valuable in determining species with various 
Mw 
• Visualization is made with Coomassie blue or silver 
nitrate 
Rituximab – DTPA-SCN 1,5
Rituximab – DOTA-SCN 2,4
Rituximab – DTPA-1B4M 3,7
Chromatography
• Affinity chromatography (Protein A HPLC)
• SE - HPLC
• Ion Exchange Chromatography
SEC chromatogram of
anti-streptavidin IgG1 
monoclonal antibody showing 
the different species of 
monomer, HMWS and 
LMWS. 
(1) C5MSu 6 months at 25°C 
(2) C5MSu 0 months at 4°C
(3) C5M 6 months 25°C 
(4) C5M 0 months 4°C
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(B) Chromatographic profile of 
the eluted fractions at 280nm 
of the freeze-dried rituximab-
1B4M-DTPA immunoconjugate
after reconstitution: a) sample 
without mannitol, b) sample 
with 10 mg/mL mannitol.
Sephadex G25 column 
(A) Chromatographic 
profile of liquid, 
purified rituximab at 
280nm
177Lu-1B4M-DTPA-rituximab
1177Lu-DTPA-rituximab
177Lu-DOTA-rituximab
ITLC -radiodetection
This research has been performed in the frames 
of the Coordinated Research Project, financed 
by the International Atomic Energy Association 
(IAEA), titled:
Establishment and standardization of a 
technology for the production of ready-
to-use cold kit formulations for labelling
DOTA-Rituximab and peptide-based 
conjugates with Lu-177 and Y-90
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